Birgitta Versluijs

142 Results The results of the univariate predictor analyses for Allo-LS free survival in the total Allo- LS group as well as in the BOS and IPS subgroups is shown in the supplemental data (see Table S1, S2, S3). Multivariate predictor analyses for Allo-LS Free survival noted worse outcome in patients who needed ICU admission for ventilator support (HR 3.61, 95% CI 1.49-8.76, p=0.005), and in those receiving systemic GvHD therapy prior to Allo- LS (HR 7.46, 95% CI 2.15-25.86, p=0.002). Patients with a positive PCR for RV at time of diagnosis of Allo-LS did better (HR 0.32, 95% CI 0.13-0.76, p=0.01). In the IPS subgroup only ICU admission and GvHD prior to Allo-LS were found to be significantly associated with bad outcome, in the BOS patients no predictors for outcome were found. (Table 2) In the total Allo-LS group we then analyzed these variables as predictors for Therapy Failure and NRM. (see Table S4, S5) Previous GVHD treatment (HR 2.63, 95% CI 0.98- 7.05, p=0.06) and ICU admission (HR 2.15, 95% CI 0.96-4.82, p=0.06) showed a trend to Therapy Failure. The presence of RV (HR 0.25, 95% CI 0.10-0.65, p=0.004) and ICU admission (HR 3.38, 95% CI 1.34-8.54, p=0.01) were associated with NRM. TABLE 2. Multivariate predictor analyses for Allo-LS Free survival. Hazard ratio (95% CI) p-value Allo-LS group (IPS + BOS)  RV from NPA or BAL at diagnosis Allo-LS 0.32 (0.13-0.76) 0.01*  Intensive care for mechanical ventilation 3.61 (1.49-8.76) 0.005*  Systemic GvHD treatment prior to Allo-LS 7.46 (2.15-25.86) 0.002* Subgroup BOS  RV from NPA or BAL at diagnosis Allo-LS 0.84 (0.16-4.50) 0.84  Intensive care for mechanical ventilation 0.68 (0.11-4.30) 0.68  Systemic GvHD treatment prior to Allo-LS 13.45 (0.65-277) 0.09 Subgroup IPS  RV from NPA or BAL at diagnosis Allo-LS 0.32 (0.09-1.1) 0.07  Intensive care for mechanical ventilation 5.23 (1.25-21.82) 0.02*  Systemic GvHD treatment prior to Allo-LS 5.80 (1.09-30.84) 0.04* Allo-LS = Alloimmune mediated lung syndrome, IPS= Idiopathic Pneumonia Syndrome, RV = Respiratory Virus, NPA = Nasal Pharyngeal Aspirate, BAL = Broncho Alveolar Lavage, BOS = Bronchiolitis Obliterans Syndrome, GvHD = Graft versus Host Disease. 8